Valneva withdraws US applications for Chikungunya vaccine IXCHIQ®
Original story from Valneva (Saint-Herblain, France).
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, have announced that the Company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ®, in the United States, following suspension of the license by the US Food and Drug Administration (FDA; MD, USA) in August 2025. The Company had been awaiting further information with respect to its formal response to the vaccine license suspension. Valneva was recently informed of the FDA’s further decision to now place the Investigational New Drug (IND) on clinical hold pending an investigation of a newly reported foreign Serious Adverse Event (SAE).
There are currently no clinical studies involving IXCHIQ® that are actively vaccinating participants, and the company intends to move forward with its planned post-marketing clinical activities, subject to further discussions with relevant regulatory authorities.
The SAE occurred outside of the US and involved a younger adult who received three concomitant vaccines, including IXCHIQ®. Based on the information made available to Valneva, which the
company submitted to the US Vaccine Adverse Event Reporting System (VAERS) as well as to all other pharmacovigilance systems in accordance with the products license, the case may be
plausibly related to IXCHIQ® vaccination, but causality has not been determined. The company is actively seeking additional information to further characterize the case.
You may also be interested in:
- CDC revamps childhood vaccine guidance
- 60-seconds with Francis Dessy & Ivo Sonderegger: Harmonization of vaccine ligand binding assays validation
- How MIT’s single-injection vaccines could replace multiple doses
Valneva is committed to upholding the highest safety standards, and the company continues to engage proactively with health authorities in all territories where IXCHIQ® is licensed, including Europe, Canada, the United Kingdom and Brazil. While IXCHIQ® is currently focused on travelers to regions where the virus is endemic, such as tropical and subtropical areas in Asia, Africa and the Americas, and persons for whom vaccination is medically justified based on risk in accordance with the approved label and vaccination guidance, the company continues to believe that IXCHIQ®’s benefit-risk profile also remains favorable for people living in the endemic and outbreak settings, where IXCHIQ® may be uniquely positioned as a highly durable single-shot vaccine.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source.
